17 November 2022 (Thursday) - Tranfusion News Update

One of the things which winds me up so much is how opinion changes. Convalescent plasma… is it good or not?

High-Titer Convalescent Plasma Increases Long-Term Survival for Patients with Severe COVID-19

November 16, 2022Randomized controlled clinical trials have evaluated the safety and efficacy of COVID-19 convalescent plasma (CCP) and found high-titer CCP reduced the risk of hospitalization if used early in the course of disease. However, little is known about the long-term effect of CCP. [Read more]


Prehospital Transfusion Programs

Join Transfusion News Associate Editors Daniela Hermelin and Monica Pagano on Twitter Space this Friday November 18 at 11:00 ET for a #Blooducation Baristas live event. They will delve into the medical data & speak directly with members of the San Antonio Blood Consortium leading the way. [Set a reminder to join us]


HbS Promotes Proinflammatory Cytokine Production in Sickle Cell Disease

November 9, 2022Unlike patients with intravascular hemolysis without sickle cell disease (SCD) or those with β-thalassemia, patients with SCD have elevated baseline levels of proinflammatory cytokines which increase during vaso-occlusive crises (VOC). Monocytes are responsible for the increased production of these cytokines, but the mechanisms behind the activation of monocytes in patients with SCD have been elusive. [Read more]


No comments:

Post a Comment